K2 Principal Fund’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-111,000
Closed -$1.61M 255
2020
Q1
$1.61M Hold
111,000
0.31% 90
2019
Q4
$2.25M Buy
+111,000
New +$1.02M 0.19% 150
2018
Q1
Sell
-12,000
Closed -$54K 320
2017
Q4
$54K Sell
12,000
-24,900
-67% -$138K ﹤0.01% 281
2017
Q3
$231K Buy
+36,900
New +$233K 0.02% 287

Other funds holding AUPH

K2 Principal Fund's AUPH Position: Q4 2022 in Review

K2 Principal Fund sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2022, closing a stake of 58,772 shares — an estimated $442K sold.

K2 Principal Fund first reported a position in AUPH in Q4 2016 and held it in 4 quarters. The position peaked at $1.81M in Q2 2021. 192 funds tracked by Wall St. Rank hold AUPH as of Q4 2022.

  • K2 Principal Fund reported no remaining Aurinia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • K2 Principal Fund sold 58,772 Aurinia Pharmaceuticals shares in Q4 2022, an estimated $442K.
  • K2 Principal Fund first reported a position in Aurinia Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • K2 Principal Fund's Aurinia Pharmaceuticals position peaked at $1.81M in Q2 2021.
  • 192 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2022.

Based on K2 Principal Fund's 13F filing for Q4 2022, filed 10 Feb 2023.